DSM BioSolutions has entered into an agreement with Novacta Biosystems Ltd. for the process development and cGMP production of its C. difficile molecule, a new class of lantibiotic compounds.

DSM has successfully completed the process development and began cGMP manufacturing of the Novacta compound at its microbial fermentation biotech facility in Capua, Italy. The product will initially be used for preclinical and Phase I trials.

Villaume Kal, vice president of DSM BioSolutions said, “We are excited to work with Novacta Biosystems, an innovative and progressive biopharmaceutical company developing treatments for infectious diseases. Our technology, operational excellence and outstanding cGMP and compliance record with the FDA allows us to serve this important customer and to produce their clinical trial material.”

Mike Dawson, chief scientific officer of Novacta said, “We have chosen to work with DSM as it has an impressive track record for scaling up fermentation processes for antibacterial agents from actinomycetes.”

Financial terms were not disclosed.

Click here to learn more about DSM